Skip to content
Brit Fortune Point

Zimbabwe Declines ‘One-Sided’ US Health Aid Agreement Due to Data Concerns

Medical funding image
The offered American financial assistance would have supported initiatives for treating and preventing HIV/Aids, TB, and malaria.

Zimbabwe has declined a major US healthcare agreement worth 367 million US dollars (£272m) spanning five years over Washington's insistence on confidential information.

The decision was revealed after a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa believed the deal was "unbalanced".

A government spokesperson later clarified that the US was demanding access to health data for scientific study and profit but refused to share the resulting advantages from future vaccines.

"We must now begin the challenging and unfortunate process of winding down our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.

The US Embassy indicated the US had furnished more than $1.9bn as health assistance to Zimbabwe over the last twenty years.

A physicians' group in Zimbabwe has urged continued talks to secure a agreement suitable to all parties so the nation's critical HIV programme can be sustained.

Broader Background

This development comes after a similar case in neighbouring Kenya, where a court blocked a related deal with the US following legal challenges were filed about the safety of Kenyans' medical information.

After returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.

USAID had administered aid for the American government, but Trump argued its spending was "inefficient" and his administration was seeking direct bilateral agreements to boost transparency and responsibility.

Based on reports, Sixteen nations in Africa have to date signed similar health pacts, constituting over $18.3bn in committed funds.

Specifics of the Declined Agreement

The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".

"We believe this collaboration could have provided extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment through American-funded initiatives," the Ambassador said.

However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".

"Our nation was requested to share its biological resources and data indefinitely, without any equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that could result from that provided information," he stated.

"Put simply, our country would supply the basic resources for medical research with no certainty that the end products would be available to our population if a future pandemic arise."

National Interest and International Frameworks

Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting structures already set up via the global health agency.

The spokesperson cited its Pandemic Benefit-Sharing scheme designed to manage future pandemics.

"This framework is intended to ensure that when a nation contributes its data, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the capability to develop them."

These objections regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.

"We encourage ongoing dialogue with our American counterparts on how subsequent collaboration might be designed in a manner that honours the sovereignty and interests of each country."

Health Experts Reaction

Medical experts said it understood the official position, but suggested that negotiations need to persist given that much of the nation's Aids initiatives were funded by external financing.

"Where technical issues exist, including those relating to information security or implementation frameworks, these can often be resolved through technical clarification and negotiated safeguards," the group said.

The halted deal emphasises the complex debate between accepting much-needed international aid and safeguarding a country's data in an increasingly data-driven world.

About the author

Claire Kelley

Eleanor Whitfield is a seasoned financial analyst with over a decade of experience writing about UK personal finance and investment strategies.

Brit Fortune Point

Type to search articles.